Yuanyuan Cao1, Xiuwen Ni2, Yong Wang3, Lejian Wang4, Kai Yuan5, Guofang Gan6, Kunming Zhang7, Zhidi Zhao7, Xianming Fei8. 1. Department of Laboratory Medicine, Hangzhou Cancer Hospital, Hangzhou 310002, China. 2. Central Blood Bank of Jiaxing, Jiaxing 314001, China. 3. Department of Laboratory Medicine, Shangyu People's Hospital of Shaoxing, Shaoxing 312300, China. 4. Department of Laboratory Medicine, Taizhou Central Hospital, Taizhou 318000, China. 5. Department of Laboratory Medicine, First Yuhuan People's Hospital, Yuhuan 317600, China. 6. Department of Laboratory Medicine, Maternity and Child Health-Care Hospital of Huzhou, Huzhou 313000, China. 7. Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, China. 8. Center of Laboratory Medicine, Zhejiang Provincial People's Hospital and People's Hospital of Hangzhou Medical College, Hangzhou 310014, China.
Abstract
BACKGROUND: Fibrinogen concentrations and the monocyte-to-lymphocyte ratio (FC-MLR) are associated with progression and outcomes of many malignancies. This study aimed to assess the clinical and prognostic significance of the combination of plasma FC-MLR in patients with ovarian cancer. METHODS: A total of 155 patients with epithelial ovarian cancer (EOC) and 102 patients with benign gynecological disease were retrospectively reviewed. The clinical and pathological data of all patients with EOC were analyzed. Plasma fibrinogen concentrations and the white blood cell (WBC) count were measured to calculate the MLR and neutrophil-to-lymphocyte ratio (NLR). Furthermore, the association of fibrinogen concentrations, the MLR, and FC-MLR with tumor stage, lymphatic and venous metastasis, and 5-year survival was assessed. Regression analysis was performed to evaluate the risk factors for progression of EOC. Receiver operating characteristic (ROC) curves were constructed to assess the prognostic power of plasma fibrinogen concentrations, the MLR, and FC-MLR, and to determine the optimal cutoff values of fibrinogen and the MLR. On the basis of the cutoff values, patients with EOC were divided into three groups: no abnormality, either increased, and both increased groups, respectively. The effect of FC-MLR on overall survival was calculated by the Kaplan-Meier method and compared by the log-rank test in the three groups. RESULTS: Patients with EOC had higher fibrinogen concentrations and a higher MLR than did controls (both P<0.01), and FC-MLR was closely associated with tumor stage and lymphatic and venous metastasis (all P<0.001). Furthermore, FC-MLR was an independent risk factor for progression of EOC (OR =8.985; 95% CI: 4.912-27.166; P<0.001), and patients with high fibrinogen concentrations and a high MLR showed a lower 5-year survival rate (P<0.001). CONCLUSIONS: FC-MLR may be used as a predictor of tumor progression and prognosis for ovarian cancer.
BACKGROUND: Fibrinogen concentrations and the monocyte-to-lymphocyte ratio (FC-MLR) are associated with progression and outcomes of many malignancies. This study aimed to assess the clinical and prognostic significance of the combination of plasma FC-MLR in patients with ovarian cancer. METHODS: A total of 155 patients with epithelial ovarian cancer (EOC) and 102 patients with benign gynecological disease were retrospectively reviewed. The clinical and pathological data of all patients with EOC were analyzed. Plasma fibrinogen concentrations and the white blood cell (WBC) count were measured to calculate the MLR and neutrophil-to-lymphocyte ratio (NLR). Furthermore, the association of fibrinogen concentrations, the MLR, and FC-MLR with tumor stage, lymphatic and venous metastasis, and 5-year survival was assessed. Regression analysis was performed to evaluate the risk factors for progression of EOC. Receiver operating characteristic (ROC) curves were constructed to assess the prognostic power of plasma fibrinogen concentrations, the MLR, and FC-MLR, and to determine the optimal cutoff values of fibrinogen and the MLR. On the basis of the cutoff values, patients with EOC were divided into three groups: no abnormality, either increased, and both increased groups, respectively. The effect of FC-MLR on overall survival was calculated by the Kaplan-Meier method and compared by the log-rank test in the three groups. RESULTS: Patients with EOC had higher fibrinogen concentrations and a higher MLR than did controls (both P<0.01), and FC-MLR was closely associated with tumor stage and lymphatic and venous metastasis (all P<0.001). Furthermore, FC-MLR was an independent risk factor for progression of EOC (OR =8.985; 95% CI: 4.912-27.166; P<0.001), and patients with high fibrinogen concentrations and a high MLR showed a lower 5-year survival rate (P<0.001). CONCLUSIONS: FC-MLR may be used as a predictor of tumor progression and prognosis for ovarian cancer.
Entities:
Keywords:
Ovarian cancer; fibrinogen concentration; monocyte-to-lymphocyte ratio (MLR)
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Glenys A Tennent; Stephen O Brennan; Arie J Stangou; John O'Grady; Philip N Hawkins; Mark B Pepys Journal: Blood Date: 2006-11-02 Impact factor: 22.113
Authors: Andrea Mari; Gianluca Muto; Fabrizio Di Maida; Riccardo Tellini; Riccardo Bossa; Claudio Bisegna; Riccardo Campi; Andrea Cocci; Lorenzo Viola; Antonio Grosso; Sabino Scelzi; Alberto Lapini; Marco Carini; Andrea Minervini Journal: Arab J Urol Date: 2020-08-26